期刊文献+

口腔鳞状细胞癌患者血清中CCL2和VEGF表达的初步研究 被引量:8

Preliminary Study on the Expression of CCL2 and VEGF in Serum of Patients with Oral Squamous Cell Carcinoma
下载PDF
导出
摘要 目的探讨口腔鳞状细胞癌(OSCC)患者血清中单核细胞趋化蛋白-1(MCP-1/CCL2)及血管内皮生长因子(VEGF)的表达及意义。方法收集27例健康对照者和85例OSCC患者的血清,用ELISA方法检测CCL2及VEGF的表达水平,分析两者相关性及与临床病理参数的关系。结果 OSCC患者血清CCL2水平为69.12±19.54 pg/ml,显著低于健康对照者(103.41±34.42 pg/ml),差异具有统计学意义(t=6.477,P<0.05)。OSCC患者血清CCL2水平与TNM分期明显相关(t=2.193,P<0.05)。OSCC患者血清VEGF水平为145.76±49.34 pg/ml,显著高于健康对照者(70.35±14.93 pg/ml),差异具有统计学意义(t=3.92,P<0.05)。CCL2水平与VEGF水平呈负相关关系(r=-0.216,P<0.05)。受试者工作特征曲线(ROC曲线)显示血清中CCL2水平及CCL2/VEGF比值都能够很好地区分健康人和OSCC患者(P<0.05),其最佳临界值分别为98.61 pg/ml及0.82。结论 OSCC患者血清中CCL2表达降低,VEGF表达增高,提示其可能与OSCC发生、发展相关。检测血清CCL2及VEGF水平可以作为OSCC的筛查指标。 Objective To study the expression and significance of monocyte chemotactic protein-1 (MCP-1/CCL2) and vascu- lar endothelial growth factor (VEGF) in serum samples of oral squamous cell carcinoma (OSCC) patients. Methods The concentrations of CCL2 and VEGF in the serum was assessed by ELISA in healthy donors (n=27) and OSCC patients (n= 85). Then analyzed the correlation between the concentrations of CCL2 and VEGF and the relationship with patients' clini- copathological characteristics. Results CCL2 concentration was lower in OSCC patients than in healthy donors (69.12 ± 19.54 pg/ml Vs 103.41 ± 34.42 pg/ml, t = 6. 477, P〈0.05). The expression of CCL2 was positively associated to TNM stage in OSCC (t= 2. 193,P〈0.05). VEGF concentration was higher in OSCC patients than in healthy donors (145.76± 49.34 pg/ml vs 70.35d:14.93 pg/ml,t=3.92,P〈0.05). There was a negative correlation between CCL2 and VEGF (r= -0. 216,P〈0.05). The receiver operating characteristic (ROC) curve suggests that CCL2 and CCL2/VEGF in serum are good diagnostic markers to discriminate healthy people from OSCC patients, the cutoff values was 98.61 pg/ml and 0.82. Conclusion The expression of CCL2 and VEGF in serum correlated to OSCC progression,and it can be a potential diagnostic biomarker for oral disease.
出处 《现代检验医学杂志》 CAS 2017年第4期64-66,71,共4页 Journal of Modern Laboratory Medicine
基金 江苏省卫生厅课题项目(H201441) 南京市科技发展计划项目(201503038) 南京市医学科技发展基金(ykk13150)
关键词 口腔鳞状细胞癌 单核细胞趋化蛋白-1 血管内皮生长因子 血清 筛查指标 oral squamous cell carcinoma CCL2 VEGF serum diagnosis
  • 相关文献

参考文献4

二级参考文献29

  • 1郑林,许伟青,姜叙诚,于颖彦,唐剑敏.结肠癌组织中TGFβ_1及其Ⅱ型受体和Smad4蛋白的表达[J].上海交通大学学报(医学版),2006,26(2):146-150. 被引量:5
  • 2Zarogoulidis K,Zarogoulidis P,Darwiche K,et al. Tr- eatment of non-small cell lung cancer (NSCLC)[J].Journal of Thoracic Disease, 2013,5 ( Suppl 4 ) : S389-S396.
  • 3Reck M, Heigener DF,Mok T,et al. Management of non-small-cell lung cancer., recent developments[J].Lancet, 2013,382 ( 9893 ) : 709-719.
  • 4Cagle PT ,Allen TC,Olsen RJ. Lung cancer biomark ers: present status and future developments [J]. Ar- chives of Pathology & Laboratory Medicine, 2013, 137(9) :1191-1198.
  • 5Rosell R,Bivona TG,Karachaliou N. Genetics and bi- omarkers in personalisation of lung cancer treatment [J]. Lancet, 2013,382 (9893) : 720-731.
  • 6Siegel R, Naishadham D, J emal A. Cancer statistics, 2013 [J]. CA-A Cancer Journal for Clinicians, 2013,63 (1):11-30.
  • 7Diederich S. Imaging beyond RECIST:CT and MRI in molecular therapies[J]. Cancer Imaging, 2012,12 ( 2 ) : 347-350.
  • 8Nishino M,Jagannathan JP, Krajewski KM,et al. Pe- rsonalized tumor response assessment in the era of molecular medicine., cancer-specific and therapy-spe- cific response criteria to complement pitfalls of RE- CIST[J]. AJR. American Journal of Roentgenology, 2012,198(4) : 737-745.
  • 9Coche E. Recist and beyond[J]. JBR BTR,2013,96 (3):167-171.
  • 10Wahl RL,Jacene H,Kasamon Y,et al. From RECIST to PERCIST: evolving considerations for PET re- sponse criteria in solid tumors[J]. Journal of Nuclear Medicine,2009,50(Suppl 1) : 122S-150S.

共引文献40

同被引文献97

引证文献8

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部